Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AKLI .38 + 61%
DARE .32 $22 million of non-dilutive capital at close provides significant capital to achieve objectives
Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Dare´ representing 50% of the future payments otherwise payable to XOMA
Transaction allows Daré to focus on advancing Phase 3 first-in-category investigational products Ovaprene®, a potential first FDA-approved hormone-free intravaginal monthly contraceptive, and Sildenafil Cream, 3.6%, a potential first FDA-approved treatment for female sexual arousal disorder through key catalysts
Previously announced royalty financing remains outstanding, bringing royalty-based capital committed to $34 million
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has closed a royalty monetization transaction with XOMA (US) LLC. Daré received $22 million in gross proceeds at close and, following a pre-specified total return to XOMA, XOMA will make upside-sharing milestone payments to Daré equal to 50% of all remaining cash flows sold to XOMA under the transaction.
“This monetization of future net royalty and net milestone payments based on net sales of XACIATO™ (clindamycin phosphate) vaginal gel 2% under our license agreement with Organon, along with a low single digit minority interest in net payments related to future revenue from our Phase 3 candidates, Ovaprene and Sildenafil Cream, accelerates potential cash flows from the future commercial success of XACIATO and such product candidates, providing us with non-dilutive capital at an opportune time to drive shareholder value through the continued advancement of Ovaprene and Sildenafil Cream, both of which are first-in-category and represent large market opportunities,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience.
“Importantly, this transaction ensures that Daré and our shareholders have the opportunity to participate meaningfully in XACIATO economics as commercialization progresses. The structure of these agreements also underscores the significant potential of Ovaprene and Sildenafil Cream, with Daré retaining the significant majority of future economics and the ability to achieve attractive margins through retained net sales and all commercial milestones. This transaction exemplifies our commitment to being creative, collaborative and opportunistic in seeking capital at an attractive cost to advance our potential first-in-category Phase 3 candidates to deliver value for all Daré stakeholders.”
The transaction involves the sale of (a) the remaining royalties and potential milestones based on net sales of XACIATO payable to Daré under its global license agreement with Organon after deducting (i) all amounts due on such royalties and milestone payments to third-party licensors, and (ii) all payments owed by Daré under its existing royalty interest financing agreement with United in Endeavour, LLC, (b) 25% of the potential $20 million payment due to Daré under its license agreement with Bayer relating to Ovaprene, in the event Bayer, in its sole discretion, elects to make the payment1, and (c) a 4% synthetic royalty on net sales of Ovaprene and a 2% synthetic royalty on net sales of Sildenafil Cream, subject to an automatic decrease to 2.5% and 1.25%, respectively, as described below. Once XOMA achieves a pre-specified total return on its investment, XOMA will pay to Daré 50% of each successive $22 million that XOMA receives under the transaction agreements, and, once XOMA achieves another pre-specified total return on its investment, the synthetic royalty rates on net sales of Ovaprene and Sildenafil Cream will automatically decrease to 2.5% and 1.25%, respectively, which, after taking into account the $11 million payments to Daré after XOMA achieves the initial pre-specified total return, results in a lower effective royalty rate.
TD Cowen, a division of TD Securities, acted as exclusive financial advisor to Daré Bioscience on the transaction. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as Daré’s legal advisor while XOMA was advised by Gibson, Dunn & Crutcher LLP.
Additional information regarding the transaction is available in Daré’s Current Report on Form 8-K filed with the Securities and Exchange Commission today.
1 - Daré retains 75% of the potential $20 million payment and has no downstream obligations with respect to such payment.
Like there style lol.. 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.36 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 2, 2024, subject to the satisfaction of customary closing conditions.
AWIN since 4.63 wasn’t bottom now we have a 3.18- 3.51 level then 4.21- 4.63 to consider
CYCC 2.25 for those still holding 2.37 -2.63 next zone of interest if breaks out of 2.32.. 1m floater
CYCC 2.31 all out of trade. 2.30s my target
CYCC 2.19 unloaded 80% so far now hold 20% for potential 2.30s
CYCC 2.06 let’s see if we get to 2.30s
CYCC 1.96 must hold at least 1.92 for me and if breaks 2.03 then 2.05- 2.37 next zone of interest
No offering…The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.
The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.
CYCC 2.03 scale out a little more
CYCC 1.91 scale out now
CYCC 1.36- 1.78
CYCC hit it low floater ….news The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.
The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.
At $7 now MULN lol it’s a short term play on EVs made in the USA by a saintly CEO and then run away from the trade. $8- $9.13 is the next level extreme high risk buyer beware
Got some EFTR nice small floater. Get ready for Yellen to blow up the markets soon they need rate cuts for votes and housing market. Only temporary rate cuts until elections.
CLDI .25 + 68% offering at .40 cents nice pump
No more no buy now WBUY .32 bottom in
Lets get a morning GRRR $4.91 bottom in
GRRR bottom in
Yellen about to do a major market pump by forcing rates down temporarily before elections….politics politics….The US Treasury's Quarterly Refunding Announcement (QRA) on how much issuance will be made has become important due to emerging concerns of developing supply/demand mismatch for longer
Markets soaring next week !!! Yellens announcement Monday or at latest Wednesday about a massive bond short squeeze they need rates down now and quickly before elections to make people stop thinking everything is expensive.
The bet still on for interest rate cut lol
LIFW .99 +5% in some …market correction stagflation looking lows don’t last long
BDRX Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the
Treatment of Familial Adenomatous Polyposis (FAP)
Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP
An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum
PEGY IVP
Pineapple HoldingsPEGY
0.0899 +73.22% 35.56M
Inspire Veterinary.IVP
0.0467 +22.57% 2.42M
Jump jump
BCSAU $19 +68% TVGN FRGT PEGY ELWS NIVF
Blockchain Coinves.BCSAU
19.00 +68.89% 78.38K
Tevogen Bio Holdin.TVGN
1.35 +58.82% 1.32M
Freight TechFRGT
1.25 +36.76% 3.73M
Pineapple HoldingsPEGY
0.071 +36.80% 17
“Today we present initial clinical data from our ongoing Phase 2 clinical trial which we believe highlights the power of our next generation proteomics-based AP3 precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “For the first time, we share statistically significant prospective validation of our AP3 patient selection approach via our ACR-368 OncoSignature assay, which demonstrated the ability to effectively identify cancer patients whose tumors are likely to respond to ACR-368 monotherapy treatment. We are extremely gratified to not only confirm the ability to identify and enrich for patient responders with ovarian cancer, but also for patients with endometrial cancer, a new tumor type identified and predicted to be sensitive to ACR-368 by our AP3 platform prior to clinical trial initiation.”
“Today’s R&D event provides us an opportunity to present the compelling preclinical data of our AP3-based, rationally-designed ACR-2316 dual WEE1/PKMYT1 inhibitor,” said Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon Therapeutics, Inc. and president and CEO of the company´s research subsidiary Acrivon AB. “We are excited to announce our accelerated timelines for IND filing, now expected in the third quarter with potential clinical study initiation now anticipated in the fourth quarter of this year. We believe this potential first-in-class asset, which is specifically designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors, has the potential to address significant unmet treatment needs against a broad range of tumors in patients with limited treatment options.”
Company Provides Program and Data Highlights:
An overview of the broad, actionable scientific capabilities and clinically demonstrated deliverables of the AP3 platform
Initial ACR-368 clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) in the ongoing registrational-intent Phase 2b trial are being presented (data cut as of April 1, 2024).
A confirmed ORR (per RECIST 1.1) of 50% was observed in the prospective cohort of OncoSignature-positive patients who were efficacy-evaluable. All confirmed responders continue to be on treatment, median duration of response (DoR) has not yet been reached. Notably, endometrial cancer is a new tumor type with significant unmet medical need that was identified and predicted to be sensitive to ACR-368 by AP3 indication screening.
Initial, prospective validation of the AP3-based ACR-368 OncoSignature assay demonstrating its ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy in the ongoing clinical trial, with clear segregation of RECIST responders in the OncoSignature-positive (50% confirmed ORR in 10 patients) versus OncoSignature-negative (0% ORR in 16 patients) arms (p-value=0.0038).
In the OncoSignature-negative arm with ovarian or endometrial cancers, encouraging signs of clinical activity were observed in response to ACR-368 with ultra-low dose gemcitabine at the recommended Phase 2 combination dose, with 8 out of 16 patients achieving stable disease.
Consistent with past trials, the ACR-368 treatment-related adverse event profile was predominantly reversible and transient with only mechanism-based, hematological adverse events.
ACR-2316, a potential first-in-class, potent WEE1/PKMYT1 inhibitor continues to advance rapidly with IND filing now expected in Q3 2024 (vs. previous guidance of Q4 2024) and the initiation of a clinical trial is anticipated in Q4 2024. ACR-2316 is uniquely designed by AP3 for superior single-agent activity and to overcome limitations of current WEE1 inhibitors and PKMYT1 inhibitors.
A preview of the AP3 Interactome, which is a proprietary, machine-learning-enabled interactive platform used to uncover actionable drug-induced pathway effects across all studies.
A live and recorded webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations. The webcast will be available for at least 30 days following the event.
ACRV $12 + 27% look for $12.10- $14.09
ILAG .77 start taking your money cash time
Not lagging for now
ILAG .70 look at .81-.89 zone to book profits first resistance to beat .68-.72 doesn’t go clear the deck
I don’t lag for now ILAG .67 + 25-%
AIRE plenty of resistance 1.13-1.21 so that’s a sell zone then 1.22- 1.37
CGC 9.21
DJT $35.38 …. 12:31 PM EDT, 04/24/2024 (MT Newswires) -- Trump Media & Technology Group (DJT) CEO Devin Nunes penned a letter to the Republican heads of various committees in the US House of Representatives, urging them to investigate the possible manipulation of the company's stock.
"Overall, we assess there are strong indications of unlawful manipulation of [Trump Media & Technology] stock," Nunes said in the letter. "As such, I respectfully request that you open an investigation of anomalous trading of [Trump Media & Technology] to determine its extent and purpose, and whether any laws, including RICO statues and tax evasion laws, were violated, so that perpetrators of any illegal activity can be held to account."
WHLM $6.97 Push it higher 33k float lol
Push it higher 33k float lol
CZOO MULN look at resistance levels and take profits quickly anything that’s automaker in big trouble as Banks not issuing auto loans anymore except for perfect credit scores..
1.92 NKGN added 1.60s earlier for the next run break 1.95- 1.97 and then 2.32-2.56 zone looks juicy
TROO 1.68 take those profits time hit the zone
TPST 3.48 look at 3.72- 3.99 for next zone and a solid break above 3.99 and sparkles could come..